Cancer Research AACR Membership  Telomeres
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 40, 1525-1531, May 1, 1980]
© 1980 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Grant, S.
Right arrow Articles by Cadman, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Grant, S.
Right arrow Articles by Cadman, E.

Enhancement of 1-ß-D-Arabinofuranosylcytosine Accumulation within L1210 Cells and Increased Cytotoxicity following Thymidine Exposure1

Steven Grant, Connie Lehman and Ed Cadman2

Departments of Medicine and Pharmacology, Section of Medical Oncology, Yale School of Medicine, New Haven, Connecticut 06510

The effect of prior exposure to thymidine (dThd) on the intracellular accumulation of deoxycytidine (dCyd) and 1-ß-D-arabinofuranosylcytosine (ara-C), as well as intracellular deoxyribonucleotide pools, was studied in suspension cultures of L1210 cells during logarithmic growth. Pretreatment with 0.1 mM dThd for 5 hr resulted in an increase in intracellular dCyd incorporation from 30 pmol dCyd per 106 cells to 220 pmol dCyd per 106 cells following 1 hr exposure to 5 µM [3H]dCyd. Under the same conditions, the intracellular incorporation of ara-C was increased from 32 pmol ara-C per 106 cells to 120 pmol ara-C per 106 cells following 1 hr exposure to 5 µM [3H]-ara-C. Utilization of a 1-hr dThd exposure time, as well as dThd concentrations of 0.01 and 2 mM, resulted in less intracellular enhancement of dCyd and ara-C incorporation. Following a 5-hr exposure to 0.1 mM dThd, the incorporation of [3H]ara-C into RNA increased from 0.21 to 0.48 pmol ara-C per µg D-ribose; DNA incorporation increased from 0.70 to 3.50 pmol ara-C per µg deoxyribose. In addition, dThd pretreatment was associated with an 8-fold increase in 1-ß-D-arabinofuranosylcytosine 5'-triphosphate production.

The maximum reduction of intracellular deoxycytidine 5'-triphosphate pools, from 106 pmol/106 cells to 25 pmol/106 cells, occurred after a 5-hr exposure of 0.1 mM dThd. This reduction in the deoxycytidine triphosphate pool was inversely correlated with the magnitude of the enhancement of intracellular ara-C incorporation. The sequence of 0.1 mM dThd for 5 hr followed by 5 µM ara-C for 1 hr resulted in a reduction in L1210 colony formation to 3% of control values, which represented synergistic cell killing relative to either drug given alone or the reverse drug sequence. Thus, dThd enhances the intracellular and nucleic acid incorporation of ara-C, most probably as a consequence of a reduction in deoxycytidine triphosphate pools, and this is the probable biochemical explanation for the enhanced in vitro cytotoxicity.

1 Supported by National Cancer Institute Grants CA 24187 and CA 09200 and a Swebilius Cancer Award from the Yale Comprehensive Cancer Center.

2 To whom requests for reprints should be addressed.

Received 9/24/79. Accepted 2/ 5/80.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1980 by the American Association for Cancer Research.